Aptinyx’s Mid-Stage NMDA Receptor Fails to Hit Endpoints in Neuropathic Pain Study
Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance.